Efficacy and Safety of Radioligand Therapy with Actinium-225 DOTATATE in Patients with Advanced, Metastatic or Inoperable Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis

<i>Background and Objectives</i>: Peptide receptor radionuclide therapy (PRRT) using radiopharmaceuticals labelled with Lutetium-177 is currently a therapeutic option for patients with advanced neuroendocrine neoplasms overexpressing somatostatin receptors (SSTRs). One promising option that has gain...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Alessio Rizzo, Alessio Imperiale, Salvatore Annunziata, Roberto C. Delgado Bolton, Domenico Albano, Francesco Fiz, Arnoldo Piccardo, Marco Cuzzocrea, Gaetano Paone, Giorgio Treglia
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	MDPI AG 2025-07-01
סדרה:	Medicina
נושאים:	neuroendocrine radioligand therapy Actinium-225 DOTATATE alpha-emitting somatostatin
גישה מקוונת:	https://www.mdpi.com/1648-9144/61/8/1341
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!